Alanine aimnotransferase hepatitis foundation of new zealand hfzn 2015

A very specific and technical topic!

The Alanine Aminotransferase (ALT) Hepatitis Foundation of New Zealand (HFZ) is a non-profit organization that aims to promote awareness, education, and research about hepatitis and liver disease in New Zealand.

Here are some key points about the HFZ and its activities in 2015:

Mission: The HFZ's mission is to reduce the incidence and impact of hepatitis and liver disease in New Zealand by promoting awareness, education, and research.

Objectives: The organization's objectives include:

  1. Raising awareness about hepatitis and liver disease among the general public, healthcare professionals, and policymakers.
  2. Providing education and support to individuals affected by hepatitis and liver disease.
  3. Advocating for policies and programs that promote the prevention, diagnosis, and treatment of hepatitis and liver disease.
  4. Funding research into the causes, diagnosis, and treatment of hepatitis and liver disease.

Activities in 2015: In 2015, the HFZ conducted several activities to achieve its objectives, including:

  1. Organizing a national hepatitis awareness campaign, which included public events, media outreach, and social media campaigns.
  2. Providing education and support to individuals affected by hepatitis and liver disease through its helpline and online resources.
  3. Advocating for policies and programs that promote the prevention, diagnosis, and treatment of hepatitis and liver disease, including submissions to government inquiries and consultations.
  4. Funding research into the causes, diagnosis, and treatment of hepatitis and liver disease, including grants to researchers and research institutions.

Key statistics: In 2015, the HFZ reported the following key statistics:

  1. Hepatitis B and C are the most common causes of liver disease in New Zealand, accounting for approximately 70% of all liver disease cases.
  2. In 2015, there were approximately 12,000 new cases of hepatitis B and 6,000 new cases of hepatitis C reported in New Zealand.
  3. The HFZ estimates that there are approximately 100,000 people living with chronic hepatitis B and 50,000 people living with chronic hepatitis C in New Zealand.

Overall, the HFZ plays an important role in promoting awareness, education, and research about hepatitis and liver disease in New Zealand, and its activities in 2015 helped to advance its mission and objectives.